Gynecological cancer survivors on chemotherapy Cancer
Conditions
Interventions
Tele-coaching and tele-education: the FoRSHE-X intervention consists of 10 weeks of social media-based education and telecoaching.
Sponsors
University of Indonesia
Eligibility
Sex/Gender
Female
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Female aged 18 years or older 2. Being diagnosed with gynecological cancer (including cervical, ovarian, uterine, vulvar, vaginal, and fallopian tube cancer) 3. Receiving chemotherapy at the DNCC 4. Having a smartphone 5. Willing and physically or cognitively able to participate in the study and follow the study procedures 6. Being able to communicate in Bahasa Indonesia
Exclusion criteria
Exclusion criteria: Patients diagnosed with severe neurological conditions such as unmanaged mental health diagnosis, current metastases to the brain, delirium, and dementia, as well as those with any prior history of receiving chemotherapy or cancer recurrence.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Recruitment rate: the number of eligible/potential participants who accept the invitation to participate in the study and sign the consent to participate in the study for at least a 10-week period. 2. Response rate: the participants’ complete responses to the questionnaire at baseline or pre-intervention time (T0), in the middle of the intervention period or at the end of working phase I (T1) and at the end of working phase II or at the end of the overall study period (T2). 3. Participation rate: the number of participant attendances in social-media educational and tele-coaching activities over the 10-week period. 4. Facilitators’ satisfaction and barriers were explored using semi-structured interviews at the end of the study period or after all digital health interventions were delivered to the participants. 5. Participant satisfaction rates measured using a study instrument adapted from the Telehealth Satisfaction Survey by AHRQ, U.S. Department of Health & Human Services at the end of the 10-week study period of telehealth interventions. 6. Attrition rate analyzed as the rate of participant retention till the end of the 10-week study period. 7. Qualitatively, participants will be interviewed for their perspectives on intervention adherence, barriers, and acceptability of the recruitment processes, intervention design, and outcome measurements at the end of the study. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Sociodemographic data of the participants (i.e. age, education, marital status, employment, ethnicity, and religious affiliation) and clinical data (i.e. gynecological cancer type and stage, and cancer treatment details) assessed at the beginning of the study period. 2. Distress measured using a Distress Thermometer from the NCCN Distress Management Panel at baseline or pre-intervention time (T0), in the middle of the intervention period or at the end of working phase I (T1) and at the end of working phase II or at the end of the overall study period (T2). 3. Knowledge and practice regarding chemotherapy side effects are measured using the chemotherapy side effect questionnaire, outlined by Almohammadi, et al. (2020), at baseline or pre-intervention time (T0), in the middle of the intervention period or at the end of working phase I (T1) and at the end of working phase II or at the end of the overall study period (T2). 4. Self-efficacy is measured using the self-efficacy for managing chronic disease 6-item scale (SEMCD6) initially developed by the Stanford Patient Education Research Center at baseline or pre-intervention time (T0), in the middle of the intervention period or at the end of working phase I (T1) and at the end of working phase II or at the end of the overall study period (T2). 5. Sexual quality of life (SQoL-F) is measured using Sexual Quality of Life-Female (SQOL-F) at baseline or pre-intervention time (T0), in the middle of the intervention period or at the end of working phase I (T1) and at the end of working phase II or at the end of the overall study period (T2). | — |
Countries
Indonesia
Contacts
Public ContactDyah Juliastuti
Outcome results
None listed